 CHARLOTTESVILLE, VA ACCESSWIRE December 19, 2019 Adial Pharmaceuticals, Inc. NASDAQ: ADIL; ADILW, a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has submitted Clinical Trial Applications CTAs to commence its first Phase 3 trial in Finland, Estonia, Latvia, Poland, Bulgaria, and Croatia. This follows the Companys recent filing of a CTA to also commence its first Phase 3 trial in Sweden, as previously announced. The planned Phase 3 trial will test AD04 as a genetically-targeted therapeutic agent for the treatment of Alcohol Use Disorder AUD. 